Vilizhi Bo-B (09887): Partner OBLENIO has administered the first batch of patients in the Phase IA clinical trial of LBL-051 for refractory autoimmune diseases.

Zhiyin Finance APP news, Vili Zhibo-B (09887) announced that its joint establishment with Aditum Bio, NewCo Oblenio Bio (Oblenio), has completed the first patient dosing in the Phase Ia clinical trial for LBL-051 (its sole asset, a trispecific T cell engager targeting BCMA, CD19, and CD3) conducted in Europe.